This inventor holds 21 USPTO granted patents and 1 EPO patent, primarily in Pharmaceutical Chemistry. Top assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.a.. Active years: 1991-2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Pomezia, IT (2001 - 2008)
- Rome, IT (1991 - 2010)
Company Filing History:
Years Active: 1991-2010
Areas of Expertise:
Title: Innovations of Fabio Giannessi in Pharmaceutical Patents
Introduction: Fabio Giannessi, an accomplished inventor based in Rome, Italy, has made significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 21 patents, Giannessi is particularly noted for his work on compounds that exhibit reversible inhibiting activity of carnitine palmitoyl-transferase. His research has the potential to impact various medical conditions, including hyperglycemia and heart diseases.
Latest Patents: Among his latest patents, Giannessi has focused on compounds of formula (I), which have displayed reversible inhibiting activity of carnitine palmitoyl-transferase. These compounds are poised to be instrumental in developing medicaments aimed at treating diseases associated with the hyperactivity of this enzyme, such as diabetes, heart failure, and ischemia.
Career Highlights: Currently, Fabio Giannessi is affiliated with Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., a prominent company in the pharmaceutical industry. His work is characterized by a commitment to research and innovation in creating effective drug formulations that cater to unmet medical needs.
Collaborations: Giannessi has worked alongside esteemed colleagues, including Maria Ornella Tinti and Francesco De Angelis. Their joint efforts represent a collaborative approach in advancing pharmaceutical science and developing solutions for complex health challenges.
Conclusion: Fabio Giannessi stands out as a notable inventor in the pharmaceutical sector, with a focus on improving medical therapies through innovative compounds. His ongoing research and patent contributions are crucial for the advancement of treatments that target serious health issues, benefiting countless patients worldwide.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
